5805-58-3Relevant academic research and scientific papers
TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY
-
Paragraph 00185, (2018/09/12)
Described herein are inhibitors of Transient Receptor Potential Canonical (TRPC) ion channels, comprising TRPC4 protein and/or TRPC5 protein, for use in combating obesity and other medical conditions, including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.
Titanium complexes bearing bidentate benzimidazole-containing ligands and their behavior in ethylene polymerization
Zaher, Damien,Tomov, Atanas K.,Gibson, Vernon C.,White, Andrew J.P.
experimental part, p. 3889 - 3896 (2009/04/06)
A series of potentially bidentate benzimidazolyl ligands of the type (Bim)CH2D (where Bim = benzimidazolyl and D = NMe2 L1, NEt2 L2, NPri2 L3, OMe L4 and SMe L5) has been reacted with Ti(NMe2)4 to give five- and six-coordinate Ti(IV) complexes of the type [(Bim)CH2D]Ti(NMe2)3 and [(Bim)CH2D]2Ti(NMe2)2, respectively. The X-ray structures of [(Bim)CH2OMe]Ti(NMe2)3, [(Bim)CH2NMe2]2Ti(NMe2)2 and [(Bim)CH2OMe)]2Ti(NMe2)2 are reported along with an evaluation of their behavior in ethylene polymerization.
